Stocks Health care IMRX
NASDAQ · Health careImmuneering Corp (IMRX)
It posted a net loss of $57.3M. In fiscal 2025 capital spending exceeded operating cash flow by $45.5M. At June 30, 2026 it held $41.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Immuneering Corp does
Immuneering Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$56M | -$1.27 | -$45.5M |
| 2024 | n/a | -$61M | -$2.04 | -$55.1M |
| 2023 | $0 | -$53.5M | -$1.88 | -$49.3M |
| 2022 | $317K | -$50.5M | -$1.91 | -$44.8M |
| 2021 | $2.1M | -$33.5M | -$2.46 | -$30.9M |
| 2021 | $2.3M | -$17M | -$3.44 | -$14.7M |
Latest SEC filings
What Immuneering Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- June 15, 2026
- June 11, 2026
- June 1, 2026Other event 8-K
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026
- May 15, 2026
- April 20, 2026Additional proxy material DEFA14A
- April 20, 2026Proxy statement DEF 14A
Questions about IMRX
What does Immuneering Corp do?
Immuneering Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMRX.
Is Immuneering Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $57.3M.
When did Immuneering Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026.
Similar companies
Follow IMRX
Get an email when Immuneering Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow IMRX: get an email when it filesWhere the numbers come from
Financial figures are the values Immuneering Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.